| TDD | Transdermal drug delivery |
| NSAI | Non-steroidal aromatase inhibitor |
| APIs | Active pharmaceutical ingredients |
| OLZ | Olanzapine |
| PEK | Perilla-ketone |
| DOTAR | 1,2-dioleoyloxy-3-trimethylammoniumpropan |
| ATRA | All-trans retinoic acid |
| PA | Phosphatidic acid |
| PEA | Phosphatidylethanol |
| PC | Phosphatidylcholine |
| PG | Phosphatidylglycerol |
| PEG | Polyethylene glycol |
| PI | Phosphatidylinositol |
| PS | Phosphatidylserine |
| PDI | Polydispersity index |
| PLGA | Poly (lactic-co-glycolic) acid |
| mPEG | Methoxypolyethylene glycol |
| PBA-G5D | Phenylboronic acid-PAMAM dendrimer |
| PTX | Paclitaxel |
| PEC | Polyelectrolyte complex |
| SLNs | Solid Lipid Nanoparticles |
| NLCs | Nanostructured Lipid Carriers |
| PELNVs | Plant exosome-like vesicles |
| ROS | Reactive oxygen species |
| VDCs | Vertical Diffusion Cells |
| MIVO® | Multi In Vitro Organ |
| PAMPA | Parallel Artificial Membrane Permeability Assay |
| PSU | Polysulfone |
| PES | Polyethersulfone |
| RHE | Reconstructed human epidermis |
| FT | Full-thickness |
| HPLC | High-Performance Liquid Chromatography |
| CLSM | Confocal Laser Scanning Microscopy |
| CRS | Confocal Raman Spectroscopy |
| DOFM | Dermal Open-Flow Microperfusion |
| Cmax | Maximum plasma concentration |
| AUC | Area Under the Curve |
| AUC0−t | Area Under the Curve from time zero to the last measurable concentration |
| AUC0−∞ | Area Under the Curve from time zero extrapolated to infinity—gives the complete systemic exposure |
| FDA | The United States Food and Drug Administration |
| EAEU | The Eurasian Economic Union |
| EEU | The Eurasian Economic Union |
| EMA | The European Medicines Agency |
| IVRT | In vitro release test |
| IVPT | In vitro permeation test |